Clinical Overview

Atrial flutter is a rapid, highly organized supraventricular tachyarrhythmia driven by a single macro-reentrant electrical circuit in the atrium. Most commonly the circuit is “typical” flutter, circling the right atrium and passing through a narrow zone near the tricuspid valve called the cavotricuspid isthmus; typical, cavotricuspid-isthmus-dependent flutter is the most common form, and within it the counterclockwise variant accounts for about 90% of cases. Because the circuit is one continuous loop rather than the chaotic, multi-wavelet activity of atrial fibrillation, the atria depolarize at a fast but strikingly regular rate of roughly 250-350 bpm (typically ~300 bpm). The AV node cannot conduct every one of these impulses through to the ventricles, so only a fraction get through, producing a fixed or variable conduction ratio (2:1, 3:1, 4:1, and so on) between the atrial rate and the ventricular rate.

Because the atria never truly empty into the ventricles at that rate, atrial flutter shares much of atrial fibrillation’s clinical weight: loss of the atrial contribution to ventricular filling, stasis-related thromboembolic and stroke risk — sources differ on how that risk compares in magnitude with atrial fibrillation, with some describing it as similar and others putting the thromboembolic probability in isolated flutter at roughly half that of fibrillation — and, if the ventricular rate stays fast for a sustained period, risk of tachycardia-mediated cardiomyopathy and heart failure. Atrial flutter and atrial fibrillation also frequently coexist in the same patient — a large share of patients newly diagnosed with flutter already have a fibrillation history, and many others go on to develop fibrillation later — so a flutter finding should prompt the same anticoagulation and monitoring mindset as fibrillation, not a lesser one.

Symptoms depend heavily on the ventricular rate and the patient’s underlying cardiac status: palpitations, fatigue, reduced exercise tolerance, shortness of breath, and lightheadedness or near-syncope are common, but well-rate-controlled flutter can also be entirely asymptomatic and picked up incidentally on a monitor.

Atrial flutter shares its risk-factor profile with atrial fibrillation: structural heart disease (valve disease, prior cardiac surgery), hypertension, heart failure, chronic pulmonary disease, hyperthyroidism, obesity, obstructive sleep apnea, and advancing age all raise risk, and it is more common in men than women.

Interpretation Guide

Key Features:

• Atrial rate ~250-350 bpm (typically ~300 bpm), remarkably regular and organized
• Ventricular rate set by the AV conduction ratio: 2:1 conduction → ~150 bpm, 3:1 → ~100 bpm, 4:1 → ~75 bpm
• No discrete P waves — replaced by continuous “sawtooth” flutter waves with no isoelectric (flat) baseline between them
• PR interval not measurable — there is no discrete P wave to measure from
• QRS complex normal and narrow (<0.12 s) unless a pre-existing bundle branch block or aberrant conduction is present
• ST segment and T waves are not primary diagnostic features of atrial flutter and are secondary to identifying the flutter waves themselves
• Ventricular rhythm is regular with a fixed conduction ratio, but can look irregular when the conduction ratio varies beat to beat

At a fixed 2:1 ratio, every other flutter wave is buried in the preceding T wave or QRS complex, so the strip can look deceptively like a regular narrow-complex tachycardia at ~150 bpm with no visible atrial activity at all. This is the single highest-yield recognition trap in atrial flutter: any unexplained, mechanically “too regular” narrow-complex tachycardia sitting right around 150 bpm should prompt a deliberate search — across multiple leads if needed — for a second, hidden flutter wave between the visible ones before it gets read out as sinus tachycardia or another SVT.

Key Leads

• Lead II, III, aVF – Best show the classic sawtooth pattern; in typical (counterclockwise) flutter the flutter waves are predominantly negative in these inferior leads.
• Lead V1 – Often shows the flutter waves as upright or biphasic, useful as a second view when the inferior leads are ambiguous or partly obscured by baseline artifact.

Differential Diagnosis

• Atrial fibrillation — also has no discrete P waves, but the atrial activity is chaotic rather than a single marching, evenly spaced sawtooth pattern, and the ventricular response is irregularly irregular rather than following a fixed or predictable conduction ratio.
• Sinus tachycardia — a regular narrow-complex rhythm at ~150 bpm is the classic mimic of 2:1 atrial flutter; sinus tachycardia should have a visible, upright P wave preceding every QRS and typically drifts gradually with activity rather than sitting fixed at a mechanically exact rate.
• Supraventricular tachycardia (SVT) — also regular and narrow, but SVT lacks organized atrial flutter waves between QRS complexes and more often starts and stops abruptly rather than being driven by a fixed atrial rate and conduction ratio.
• Atrial tachycardia — produces discrete P waves separated by a flat, isoelectric baseline at a slower atrial rate than flutter, whereas flutter’s atrial waves run together with no isoelectric segment between them.

Treatment Brief

Confirm lead placement and obtain a longer strip or a full 12-lead before treating an unexplained ~150 bpm narrow-complex tachycardia as sinus in origin — hunting for buried flutter waves is the key monitoring step. Correlate the rhythm with vital signs and symptoms, and notify the provider for a new or unstable finding.

A defining practical difference from atrial fibrillation: pharmacologic rate control is harder to achieve in flutter, because the flutter circuit fires continuously at a rate the AV node struggles to blunt. Beta-blockers and non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are still used to slow a fast ventricular response, but often only partially. For that reason, electrical conversion — synchronized cardioversion or overdrive pacing — is the treatment of choice for most patients with an initial episode, and is mandatory with 1:1 AV conduction or hemodynamic compromise. Longer term, antiarrhythmic medication or, more effectively, catheter ablation of the cavotricuspid isthmus is the physician-directed option for keeping the rhythm stable. Because of the stroke risk from atrial stasis, anticoagulation guidelines make no distinction between atrial flutter and atrial fibrillation, so patients are managed with the same anticoagulation priority, particularly before any cardioversion attempt.